OSE IMMUNOTHERAPEUTICS |
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
| 7.25 EUR | +8.21% |
|
+11.88% | +69.39% |
| Apr. 17 | OSE: licensing agreement with AbbVie enters into force | CF |
| Apr. 17 | OSE Immunotherapeutics Finalizes Drug License, Collaboration Deal With AbbVie | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
End-of-day quotes
End-of-day quotes
Sector Other Biotechnology & Medical Research
| Capi. | Sales growth | Profitability | Finances | EV / Sales | P/E ratio | |
|---|---|---|---|---|---|---|
| 156M | - | |||||
| 48.16B | - | |||||
| 41.73B | ||||||
| 41.03B | ||||||
| 28.77B | ||||||
| 25.59B |
